Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Br J Psychiatry. 2018 Sep;213(3):548–554. doi: 10.1192/bjp.2018.101

Table 2.

Clinical characterisation of participants with BD-I and BD-I

BD-I n=32 BD-II n=34 Group comparison
Age first episode, mean (sd) 19 (5.8) 19 (7.0) t (50) = 0.21, p>.1
Age diagnosis, mean (sd) 30 (6.9) 34 (9.5) t (54) = 1.24, p>.1
Co-diagnosis of anxiety disorder, n (%) 12 (38%) 10 (29%) χ2 (1) = 0.49, p>.1
Medication*
     Non-medicated, n (%) 1 (3%) 8 (24%) χ2 (1) = 5.60, p<.05
     Antidepressants, n (%) 16 (50%) 15 (44%) χ2 (1) = 3.65, p>.1
     Lithium, n (%) 8 (25%) 7 (21%) χ2 (1) = 2.49, p>.1
     Anticonvulsants, n (%) 16 (50%) 15 (44%) χ2 (1) = 3.65, p>.1
     Antipsychotics, n (%) 20 (63%) 7 (21%) χ2 (1) = 12.88, p<.001
     Combination of above, n (%) 22 (69%) 14 (41%) χ2 (1) = 5.82, p<.05
*

Medication data from 1 BD-I participant was inaccessible.